Seeking Alpha

Shares of BioDelivery Sciences (BDSI) shoot up 33% premarket after the firm announces a...

Shares of BioDelivery Sciences (BDSI) shoot up 33% premarket after the firm announces a worldwide license and development agreement with Endo Pharmaceuticals (ENDP) for the rights to commercialize chronic pain treatment BEMA Buprenorphine.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs